[19 September 2017]
A report – “Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including Mycobacterium tuberculosis” – launched today by the World Health Organization (WHO) shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.
[19 September 2017]
[Berlin – 4 September 2017]
Germany hosts pledging event for GARDP, a new initiative to develop new antibiotic treatments
Germany together with a number of countries and foundations today pledged EUR 56.5 million to help develop new treatments to fight against antibiotic resistance, during a fundraising event for the Global Antibiotic Research and Development Partnership (GARDP), hosted in Berlin by the German Federal Ministry of Health and the German Federal Ministry of Education and Research.
[Geneva – 7 July 2017]
Joint WHO and GARDP/DNDi News Release: Data from 77 countries show that antibiotic resistance is making gonorrhoea – a common sexually-transmitted infection—much harder, and sometimes impossible, to treat.
[Boston, Geneva – 6 July 2017]
First partnering deal for newly-created GARDP with Entasis includes access and stewardship strategy to tackle drug-resistant gonorrhea
Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhea will enter pivotal trials, thanks to a new partnership between the not-for-profit Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. The announcement comes as the World Health Organization (WHO) releases alarming new data today showing that of 77 countries surveyed across the world, more than 60% report resistance to the last-resort treatment for gonorrhea.
[Deutsch] [Français] [Português]
[24 May 2016 – Geneva, Switzerland]
A new joint initiative by the WHO and DNDi that seeks to develop new antibiotic treatments to address the major public health threat of antimicrobial resistance announced today that it has received the necessary seed funding to build its scientific strategy, initial R&D portfolio, and start-up team.